Ursodeoxycholic acid product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 14:16
Ursodeoxycholic acid product-specific bioequivalence guidance
Prasugrel product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 14:13
Prasugrel product-specific bioequivalence guidance
Paracetamol product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 14:08
Paracetamol product-specific bioequivalence guidance
Oseltamivir product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 14:07
Oseltamivir product-specific bioequivalence guidance
Metformin product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 14:00
Metformin product-specific bioequivalence guidance
Dabigatran etexilate product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 13:55
Dabigatran etexilate product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Levetiracetam ratiopharm, levetiracetam, Date of authorisation: 26/08/2011, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 30 June 2025 - 13:34
Human medicines European public assessment report (EPAR): Levetiracetam ratiopharm, levetiracetam, Date of authorisation: 26/08/2011, Revision: 16, Status: Authorised
Annual activity report 2024
Submitted by Anonymous (not verified) on 30 June 2025 - 13:32
Annual activity report 2024
Real-world evidence
Submitted by Anonymous (not verified) on 30 June 2025 - 13:15
Real-world evidence
Memantine product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 June 2025 - 13:11
Memantine product-specific bioequivalence guidance